O ver activation of the renin-angiotensin system (RAS) is a potential mechanism linking hypertension and the development of insulin resistance. Angiotensin (Ang) II promotes hypertension by inducing AT 1 receptor-mediated vasoconstriction, renal fluid and salt retention, and sympathetic activation. 1 Enhanced systemic RAS activity is also observed in obese and diabetic patients and closely correlates with insulin resistance.
O ver activation of the renin-angiotensin system (RAS) is a potential mechanism linking hypertension and the development of insulin resistance. Angiotensin (Ang) II promotes hypertension by inducing AT 1 receptor-mediated vasoconstriction, renal fluid and salt retention, and sympathetic activation. 1 Enhanced systemic RAS activity is also observed in obese and diabetic patients and closely correlates with insulin resistance. 2 Ang II promotes insulin resistance by decreasing insulin-stimulated glucose uptake in peripheral tissues, inhibiting insulin-mediated suppression of hepatic glucose production, and impairing insulin signaling. 2 Therapies that block Ang II activity (angiotensin-converting enzyme [ACE] inhibitors and AT 1 receptor antagonists] reduce incidence of new-onset type II diabetes mellitus in randomized clinical trials. 3 These drugs also increase levels of Ang-(1-7), a peptide that counter-regulates Ang II actions, which may contribute to their beneficial cardiometabolic effects. 4 Ang-(1-7) binds the G-protein-coupled receptor mas to produce vasodilatory, antihypertensive, sympatholytic, and cardioprotective effects. 4 Accumulating evidence suggests that activation of the Ang-(1-7)/mas axis also improves glucose homeostasis. Chronic peripheral or central Ang-(1-7) infusion lowers blood pressure (BP) and improves glucose tolerance in fructose-fed rats. [5] [6] [7] Conversely, global mas receptor and ACE2 deletion, both of which reduce Ang-(1-7) activity, induce a metabolic syndrome-like phenotype in mice. 8, 9 These studies support the potential for targeting Ang-(1-7) in cardiometabolic disease. The precise mechanisms and BP dependence of Ang-(1-7) effects on insulin action, however, remain unclear.
We hypothesized that Ang-(1-7) would improve insulin sensitivity during progression of cardiometabolic syndrome, when levels of the peptide are deficient, 10 by enhancing peripheral glucose delivery. To test this, we performed hyperinsulinemic-euglycemic clamps in high-fat diet (HFD) and chow-fed mice after chronic peripheral Ang-(1-7) administration. We demonstrate that Ang-(1-7) produces BP-independent improvement in whole-body insulin sensitivity in HFD mice by enhancing insulin-stimulated muscle glucose uptake (MGU). In contrast to our hypothesis, this improvement was not because of changes in glucose delivery but instead was associated with increased glucose transporter 4 (Glut4) levels at the myocyte plasma membrane (sarcolemma).
Methods
These studies were approved by the Vanderbilt Institutional Animal Care and Use Committee and conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Detailed Methods are available in the onlineonly Data Supplement.
Mouse Models
Six-week-old C57BL/6J male mice (Jackson Laboratory) were fed standard chow (5001 Laboratory Rodent Diet) or 60% HFD (Bioserv F3282) ad libitum for 11 weeks. After 8 weeks of diet, subcutaneous osmotic minipumps (Alzet Model 2004) were implanted to deliver Ang-(1-7) (400 ng/kg per minute; Bachem) or saline vehicle for 3 weeks.
Assessment of Body Composition, Hemodynamics, and Cardiac Function
Body composition was determined after 2 weeks of treatment using an mq10 nuclear magnetic resonance analyzer (Bruker Optics). Transthoracic echocardiography was also performed at this time point using a Sonos 5500 system (Agilent). BP and heart rate were measured via an indwelling carotid artery catheter connected to a transducer and a BPA-400 analyzer (Digi-Med).
Hyperinsulinemic-Euglycemic Clamps (Insulin Clamps)
Insulin clamps were performed in conscious, unstressed, chronically catheterized mice as previously described. 11 Mice were fasted for 5 hours before starting the insulin clamp. A [3- 3 H]glucose (0.04 μCi/ min; Perkin Elmer) infusion was starting at t=−90 minutes to determine rates of plasma glucose appearance (R a ) and disappearance (R d ). At t=0 minutes, continuous insulin (4 mU/kg per minute; Humulin R; Eli Lilly) and variable glucose (D50+50 μCi [3- 3 H]glucose) infusions were initiated. From time t=0 to 120 minutes, arterial glucose was measured every 10 minutes, with the exogenous glucose infusion rate adjusted to maintain euglycemia (130-150 mg/dL). Steady-state glucose infusion rate and H]glucose kinetics were determined from t=80 to 120 minutes. Arterial blood samples were taken at baseline (basal) and during steady state (clamp) to measure insulin and nonesterified fatty acid (NEFA) levels. At t=120 minutes, mice received an intravenous bolus of 2[ 14 C]deoxyglucose (2[ 14 C]DG; 13 μCi; Perkin Elmer) to determine the tissue-specific glucose metabolic index (R g ).
Analysis of Plasma and Tissue Samples From Insulin Clamp
Insulin was measured by double antibody radioimmunoassay 12 and NEFA by enzymatic colorimetric assay (NEFA C Kit; Wako Chemicals). 3[ C]2DG-6-phosphate radioactivity were measured using liquid scintillation counting. EndoR a and R d were calculated using non-steady-state equations. 13 R g was calculated as previously described.
14 Immunostaining CD31, Glut4, and Cav3 immunostaining were assessed in formalin-fixed, paraffin-embedded, 5-μm gastrocnemius muscle sections using anti-CD31 (BD Biosciences), anti-Glut4 (Abcam), and anti-Cav3 (Santa Cruz) antibodies. CD31 staining was visualized with EnVision+HRP/DAB System (Dako). Glut4 and Cav3 staining were visualized with fluorescent secondary antibodies. Image analysis was performed using ImageJ (National Institutes of Health).
Immunoblotting
Gastrocnemius homogenates were resolved on SDS-PAGE gels, transferred to polyvinylidene fluoride membranes, and probed with phosphorylated Akt (Ser 473 ; Cell Signaling), total Akt (Cell Signaling), phosphorylated AS160 (Ser 588 ; Cell Signaling), and total AS160 (Millipore) antibodies.
Microspheres
In a separate cohort of HFD mice (n=4 vehicle, n=3 Ang- [1] [2] [3] [4] [5] [6] [7] ), 100 μL of yellow 15-μm microspheres (Dye-Trak, Triton Technology) were injected into the carotid artery after the last sampling time point of the insulin clamp to measure regional blood flow to the hindlimb.
Circulating Ang Peptide Levels
Plasma Ang-(1-7) and Ang II levels were measured in a separate cohort of mice that did not undergo insulin clamps (n=6 chow-fed vehicle; n=6 chow-fed Ang-(1-7); n=8 HFD vehicle; and n=8 HFD Ang-(1-7)] by radioimmunoassay.
Statistical Analysis
Data are presented as mean±SEM. Analyses were performed using Prism (Version 6.0, GraphPad), with a 2-tailed P value of <0.05 defined as statistical significance. Differences in outcomes were compared using unpaired t test or 2-way ANOVA with Tukey post hoc tests.
Results

Effect of Ang-(1-7) on Cardiovascular Indices
Plasma Ang-(1-7) was reduced in HFD versus chow-fed mice (Table 1 ; P=0.045 diet effect). Chronic Ang-(1-7) infusion restored HFD-induced reductions in the peptide to ≈70% of levels seen in chow-fed mice. There were significant diet (P=0.015) and interaction (P=0.004) effects for plasma Ang II, which were driven entirely by increased Ang II levels in chow-fed mice after Ang-(1-7) treatment. HFD mice had increased systolic (P=0.001), diastolic (P=0.039), and mean (P=0.001) BP, with no difference in heart rate (P=0.129). There was no effect of Ang-(1-7) on BP or heart rate in chowfed or HFD mice ( Table 1) .
Effect of Ang-(1-7) on Metabolic Indices
Body weight and adiposity were higher in HFD mice (P=0.001 diet effect; Table 2 ). Ang-(1-7) did not alter body weight in HFD or chow-fed mice; however, there was a small reduction in adiposity (P=0.040 drug effect). HFD mice had higher basal arterial glucose and insulin (P=0.018 and P=0.001 diet effect, respectively), with no difference in NEFA. Ang-(1-7) tended to lower basal insulin (P=0.055 drug effect), but did not alter fasting glycemia or NEFA. During steady-state hyperinsulinemia, glucose was clamped at ≈140 mg/dL in both HFD and chow-fed mice ( Figure 1A and 1B). HFD mice maintained higher insulin levels during the clamp (P=0.002 diet effect; Table 2 ), compared with chow-fed mice. Ang-(1-7) did not alter clamp glucose and insulin levels, but significantly enhanced insulin-mediated suppression of NEFA (P=0.001 drug effect; Table 2 ).
Ang-(1-7) Reverses HFD-Induced Skeletal Muscle Insulin Resistance
The glucose infusion rate required to maintain euglycemia during steady-state hyperinsulinemia, a measure of wholebody insulin sensitivity, was similar after Ang-(1-7) versus saline treatment in chow-fed mice (Figure 1C and 1E; P=0.143). As expected, HFD mice had lower whole-body insulin sensitivity compared with chow-fed mice (P=0.001). Ang-(1-7) doubled the glucose infusion rate required to maintain euglycemia in HFD mice (Figure 1D and 1F; P=0.017). This enhanced whole-body insulin sensitivity was because of increased insulin-stimulated peripheral glucose disposal (R d ; Figure 2A ; P=0.049). There was no effect of Ang-(1-7) on insulin-mediated suppression of endogenous glucose production (Endo Ra ; Figure 2B ; P=0.476). Consistent with effects on peripheral glucose disposal, Ang-(1-7) augmented insulinstimulated glucose uptake (R g ) in soleus, gastrocnemius, and vastus muscles in HFD mice, with no effect in epididymal adipose or cardiac tissue ( Figure 2C and 2D). Ang-(1-7) did not alter R d , Endo Ra , or R g in chow-fed mice ( Figure S1 ).
Ang-(1-7) Does Not Improve Measures of Perfusion in HFD Mice
To determine if the Ang-(1-7)-mediated improvement in insulin sensitivity was because of improved vascular glucose delivery, we measured indices of skeletal muscle (SkM) perfusion in HFD mice. Levels of a capillary density (CD31) marker were not different in gastrocnemius muscle after Ang-(1-7) treatment ( Figure S2A and S2B). Hindlimb perfusion, measured by deposition of colored microspheres at the end of the insulin clamp, was not different between treatment groups ( Figure S2C ). Finally, Ang-(1-7) did not alter cardiac function (Table S1 ).
Ang-(1-7) Enhances Sarcolemmal Glut4 Translocation in HFD Mice
A critical step in insulin-stimulated MGU is translocation of Glut4 from intracellular vesicles to the sarcolemma. To determine if Ang-(1-7) improves SkM insulin sensitivity by increasing sarcolemmal Glut4 levels, we measured Glut4 abundance within the region demarcated by the sarcolemmal marker Cav3 in gastrocnemius muscle ( Figure 3A ). Ang-(1-7) increased mean Glut4 fluorescence at the muscle plasma membrane in HFD mice ( Figure 3B ; P=0.011). This increased Glut4 trafficking was Data are mean±SEM and were analyzed by 2-way ANOVA for diet effect (P Diet ), drug effect (P Drug ), and their interaction (P Int ). Ang indicates angiotensin; DBP, diastolic blood pressure; HFD, high-fat diet; MBP, mean BP; and SBP, systolic BP. Data are mean±SEM and were analyzed by 2-way ANOVA for diet effect (P Diet ), drug effect (P Drug ), and their interaction (P Int ). Metabolic hormones were measured in arterial blood at baseline (basal), and during steady state of hyperinsulinemic-euglycemic clamps (clamp). Ang indicates angiotensin; HFD, high-fat diet; and NEFA, nonesterified fatty acids. associated with reduced total AS160 protein, a negative regulator of Glut4 translocation ( Figure 3C ; P=0.034), with no effect on phosphorylated AS160 (P=0.999). Ang-(1-7) did not alter phosphorylated or total Akt in HFD mice ( Figure S4 ).
Discussion
The main finding of this study is that chronic systemic Ang-(1-7) administration reverses HFD-induced whole-body insulin resistance by enhancing insulin-stimulated MGU. These insulin-sensitizing effects of Ang-(1-7) on SkM were associated with increased sarcolemmal Glut4 levels and downregulation of AS160, a negative regulator of Glut4 translocation. Importantly, these effects occurred independent of changes in body weight, BP, and measures of systemic and regional perfusion. Taken together, these findings provide evidence for BP-independent effects of Ang-(1-7) on insulin action, and further support targeting this peptide to treat insulin resistance in cardiometabolic disease.
Numerous previous studies using intraperitoneal glucose and insulin tolerance tests have demonstrated that activation of the Ang-(1-7)/mas axis improves whole-body glucose homeostasis. [5] [6] [7] 15 These tests involve several variables, including intestinal glucose absorption, glucose-stimulated insulin secretion, insulin sensitivity, glucose effectiveness, and counter-regulatory responses. Here, we specifically measured the contribution of insulin sensitivity to Ang-(1-7)-induced improvements in glucose tolerance using insulin clamps. Moreover, by combining the insulin clamp with isotopic glucose tracers, as in this study, we are able to assess tissuespecific insulin action. Using this gold standard method, we provide evidence that restoration of physiological Ang-(1-7) levels improves whole-body insulin sensitivity in a wellestablished animal model of cardiometabolic syndrome that exhibits mild hyperglycemia, hyperinsulinemia, insulin resistance, and modest hypertension. 16 We did not observe an effect of chronic Ang-(1-7) in chow-fed mice, in contrast to reports Figure 1 . Angiotensin-(1-7) improves whole-body insulin sensitivity in high-fat diet (HFD) mice. A and B, Arterial glucose levels were maintained at ≈140 mg/dL during insulin clamps by variable venous infusion of 50% glucose. C and D, The glucose infusion rate (GIR) needed to maintain euglycemia, a measure of whole-body insulin sensitivity, during the 120 minutes period of the insulin clamp. E, There was no effect of Ang-(1-7) on mean steady-state GIR (measured from t=80-120 minutes of the insulin clamp) in chow fed mice. F, Ang-(1-7) significantly increased the mean steady-state GIR in HFD mice.
showing acute intravenous Ang-(1-7) enhances insulin sensitivity in lean anesthetized rats. 17, 18 This may reflect differences in species and methodology, as well as compensatory mechanisms to prolonged Ang-(1-7) elevation, including mas receptor internalization. 19 Interestingly, Ang-(1-7) did not alter the mild fasting hyperglycemia induced by HFD feeding in this study. The first response, however, to increased insulin action is compensation by the endocrine pancreas. This is evidenced by an initial reduction in insulin, without changes in blood glucose or hemoglobin A1c levels. 20 In our study, Ang-(1-7)-treated mice had ≈20% lower fasting insulin levels than vehicletreated mice. Similarly, short-term Ang-(1-7) treatment (2-4 weeks) lowers plasma insulin levels in fructose fed rats, but does not lower fasting glycemia. 5, 7 Longer-term Ang-(1-7) treatment (8-24 weeks) lowers both fasting insulinemia and glycemia in animal models of cardiometabolic syndrome. 7, 15 Thus, an improvement in insulin sensitivity precedes and contributes to normalization of glycemia. In our study, it is likely glycemia would have been lowered with more prolonged Ang-(1-7) treatment.
The reason for maintained hyperglycemia after shortterm Ang-(1-7) treatment is unclear. It is conceivable that an increase in basal glucose transport and delivery would increase MGU and normalize fasting glycemia. In this study, both sarcolemmal Glut4 levels and SkM perfusion were measured under the insulin-stimulated conditions. It is not likely that the lack of effect of Ang-(1-7) on SkM perfusion in our study would contribute to the preserved basal hyperglycemia, given that an increase in glucose delivery in the absence of hyperinsulinemia has no impact on glucose uptake. 21 Importantly, an improvement in insulin sensitivity alone has beneficial effects on cardiometabolic health. For example, insulin sensitivity is a stronger predictor of type 2 diabetes development compared with fasting glucose or hemoglobin A1c. 22, 23 Furthermore, insulin sensitivity is a stronger risk factor for cardiovascular disease than hyperglycemia. 24 Over activation of the RAS, and in particular Ang II, is associated with development of SkM and hepatic insulin resistance. 25, 26 We found that chronic Ang-(1-7) infusion improves insulin-stimulated MGU in HFD mice. This corroborates in vitro studies showing that Ang-(1-7) potentiates insulin-stimulated MGU in normal rodents and reverses Ang II-induced muscle insulin resistance. 9, 27 Ang-(1-7) did not alter basal or insulin-stimulated hepatic glucose output in HFD mice, which was normal in HFD compared with chow-fed mice. The lack of hepatic insulin resistance in HFD mice is consistent with previous reports from our group. 28, 29 This is probably because of the high physiological insulin dose infused during clamps, which could mask more subtle effects of Ang-(1-7) on hepatic insulin sensitivity. Ang-(1-7) reduced adiposity and improved insulin-stimulated suppression of lipolysis in our study, consistent with reports showing improved adipose insulin action. 5, 15 Although there was no effect of Ang-(1-7) on adipose glucose uptake during insulin clamps, one cannot rule out an indirect contribution of reduced adiposity to improved insulin sensitivity.
It is unclear to what extent the vascular effects of Ang-(1-7) contribute to its metabolic effects. Ang-(1-7) promotes endothelial-dependent vasodilation in macro-and 1-7). Sections were stained for Cav3 (green) and Glut4 (white), and images were obtained by confocal microscopy. B, Ang-(1-7) increased sarcolemmal Glut4, measured as the mean Glut4 fluorescence intensity in the region demarcated by Cav3 staining. C, Immunoblot of gastrocnemius extracts from clamped HFD vehicle and Ang-(1-7)-treated mice. Ang-(1-7) decreased total AS160 protein levels, with no effect on phosphorylated AS160.
by guest on August 24, 2017 http://hyper.ahajournals.org/ Downloaded from microvessels. 4 The improved glucose tolerance in fructosefed rats with Ang-(1-7) was associated with BP lowering, 5, 6 which could indicate vasodilation and manifest as improved glucose delivery and insulin sensitivity. Ang-(1-7) did not alter BP or cardiac function, however, in HFD mice. The lack of a depressor effect in our model is consistent with accumulating evidence showing that the antihypertensive effect of Ang- (1-7) is not apparent in all research models. There are several potential reasons for varying BP effects with Ang- (1-7) , including species differences, diet, and dose, duration, and route of treatment. The discrepancy between the 2 previous studies and our results most likely reflects differences in animal models. Fructose-fed rats do not gain weight during the first 8 weeks feeding and, for the most part, develop isolated systolic hypertension. 30 In contrast, HFD-fed mice have ≈5× more adiposity than their lean counterparts and develop both systolic and diastolic hypertension. The hypertension in these 2 models may, therefore, be driven by different mechanisms with varying sensitivity to Ang-(1-7).
Ang-(1-7) could also influence regional perfusion to improve insulin sensitivity. Indeed, acute Ang-(1-7) increases muscle microvascular perfusion in normal rats. 18 We were unable to detect differences in insulin-stimulated muscle perfusion after Ang-(1-7) in HFD mice. There are several possible explanations: (1) previous studies used acute intravenous Ang-(1-7) and were done under anesthesia, 18 which alone has hemodynamic effects; (2) the ability of acute Ang-(1-7) to promote peripheral vasodilation could be lost after prolonged exposure; (3) although microsphere deposition is the gold standard for assessing microvascular perfusion in conscious animals, it may not give the resolution necessary to detect small changes; (4) the mild hyperglycemia in HFD mice may contribute to endothelial dysfunction, thus preventing Ang-(1-7) vasodilatory actions; and (5) Ang-(1-7) may improve other aspects of endothelial function that enhance SkM insulin action, such as transendothelial insulin transport from capillaries to the myocyte surface.
Given that we did not observe changes in perfusion, we examined direct effects of Ang-(1-7) on SkM. A critical component of SkM insulin action is partitioning of Glut4 to the sarcolemma to enhance glucose transport. 31 Chronic Ang-(1-7) potentiated insulin-stimulated Glut4 translocation in HFD mice, thereby increasing glucose transport into myocytes. This is consistent with previous reports demonstrating effects of Ang-(1-7) on Glut4. Namely, ACE2 deletion in mice reduces SkM Glut4 expression, an effect reversed by Ang-(1-7) infusion. 9 Furthermore, ACE inhibition, which increases Ang-(1-7) levels, improves insulin sensitivity by enhancing Glut4 translocation. 32 Insulin stimulates Glut4 translocation via activation of the PI3K/ Akt pathway. Ultimately, Akt phosphorylates and inactivates AS160 (a Rab GTPase-activating protein) to allow Glut4-containing vesicles to fuse with the sarcolemma. 33 In normal and fructose-fed rats, Ang-(1-7) stimulates Akt phosphorylation in insulin-sensitive tissues. 5, 34, 35 In addition, Ang-(1-7) increases AS160 phosphorylation in normal and diabetic rats. 34, 36 In our study, Ang-(1-7) reduced AS160 protein levels, which functionally promotes increased Glut4 at the myocyte plasma membrane, 37 independent of changes in classical Akt signaling. The precise mechanism suppressing AS160 levels is unclear, but may involve transcriptional regulation.
There are some potential limitations to these studies. We did not examine receptor and related intracellular signaling mechanisms involved in Ang-(1-7) metabolic effects. The literature suggests that most, if not all, of Ang-(1-7) actions in vivo are mediated by mas receptors. 38 Indeed, the ability of Ang-(1-7) to augment insulin-mediated glucose disposal is mas-dependent in anesthetized rats. 18 There is an evidence, however, that AT 2 receptors participate in complex vascular effects of Ang- (1-7) . Furthermore, because of limitations in blood volume sampling in mice, we were unable to measure all components of the circulating RAS. The few studies examining Ang-(1-7) effects on RAS components showed no effect on renin activity in lean rats 39 and reduced aldosterone in fructose-fed rats. 7 We observed significant plasma Ang II elevations after Ang-(1-7) infusion in chow-fed mice, with no effect in HFD mice. A similar elevation was observed in lean rats and thought to reflect a homeostatic feedback response. 39 Finally, it should be noted that the HFD had lower sodium content compared with the control diet. Despite lower sodium, HFD mice exhibited a cardiometabolic syndromelike phenotype and did not have increased RAS components. Furthermore, all HFD mice were fed the same diet, indicating the improved insulin sensitivity with Ang-(1-7) was sodium independent.
In summary, these studies show that chronic Ang-(1-7) reverses diet-induced muscle insulin resistance by enhancing insulin-stimulated Glut4 translocation. Importantly, these effects occurred even when giving a dose of Ang-(1-7) that does not lower BP. These findings provide evidence for divergence between Ang-(1-7) effects on BP and glucose metabolism, and support the growing notion that the RAS influences whole-body physiology beyond control of BP.
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Perspectives
The worldwide prevalence of insulin resistance secondary to obesity is alarmingly high. Thus, there is an urgent need to understand molecular mechanisms contributing to obesity-associated insulin resistance and related cardiovascular comorbidities. Therapies that block Ang II actions have emerged as an important strategy to lower BP in obese patients because of their positive metabolic profile. 3 The positive metabolic effects of these therapies, however, may also reflect elevated Ang-(1-7) levels. 4 Animal models of cardiometabolic syndrome have reduced circulating levels of Ang-(1-7), 10 and modulation of the Ang-(1-7)/ACE2/mas receptor axis improves glucose metabolism. We extend these findings by showing that Ang-(1-7) has direct insulin-sensitizing effects on SkM in obese mice, which are BP independent. These findings enhance our understanding of RAS mechanisms involved in regulation of insulin action, and provide new insight into the potential for targeting Ang-(1-7) in cardiometabolic disease.
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Disclosures
• Chronic angiotensin-(1-7) administration reverses diet-induced muscle insulin resistance by enhancing insulin-stimulated glucose transporter 4 translocation. Importantly, these insulin-sensitizing effects are independent of changes in body weight and blood pressure.
What Is Relevant?
• These findings provide new insight into tissue-specific mechanisms by which angiotensin-(1-7) improves insulin action in an animal model of cardiometabolic syndrome, and enhance our understanding of reninangiotensin mechanisms involved in glucose homeostasis.
Summary
This study provides new evidence for blood pressure-independent effects of angiotensin-(1-7) to improve skeletal muscle insulin action in obese mice. These findings provide further support for targeting angiotensin-(1-7) in treatment of cardiometabolic disease. Labeling controls for CAV3/GLUT4 immunofluorescence staining. Representative micrographs of gastrocnemius sections obtained following hyperinsulinemic-euglycemic clamps in high-fat fed mice. Images were obtained by confocal microscopy to demonstrate specificity of secondary antibodies for the appropriate primary antibody. All control sections were treated with both AlexaFluor555-conjugated goat anti-mouse and AlexaFluor647-conjugated goat anti-rabbit secondary antibodies. The left column represents sections not treated with any primary antibodies (no primary control). The sections in the middle and right columns were treated with either CAV3 or GLUT4 primary antibodies, respectively; to ensure that secondary antibodies only recognized the correct primary antibody.
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